Scott Gottlieb weighs in on insurers taking a chance on biosimilars, OTC reform and the timing of his departure from FDA

The explosion of tobacco use among kids, biosimilars, OTC reform and ongoing efforts to address high prescription drug prices are among areas of unfinished business as Food and Drug Commissioner Scott Gottlieb prepares to leave his post. During a conversation at The Brookings Institution on Tuesday reflecting on his approximately two-year stint as commissioner, Gottlieb said his final day will likely be April 5 to allow him time to testify on his agency's budget before a congressional committee on April 3. "There's no one else who wanted to do it," Gottlieb joked. He said he has not yet determined where he will go next but said he is planning a trip with his family to Disney World.